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Proximity ligation assay to study protein–protein
interactions of proteins on two different cells
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Protein–protein interactions (PPI) by homo-, hetero- or oligo-merization in the cellular environment regulate
cellular processes. PPI can be inhibited by antibodies, small molecules or peptides, and this inhibition has
therapeutic value. A recently developed method, the proximity ligation assay (PLA), provides detection of
PPI in the cellular environment. However, most applications using this assay are for proteins expressed in
the same cell. We employ PLA for the first time to study PPI of cell surface proteins on two different cells.
Inhibition of PPI using a peptide inhibitor is also quantified using this assay; PLA is used to detect PPI of CD2
and CD58 between Jurkat cells (T cells) and human fibroblast-like synoviocyte-rheumatoid arthritis cells that
are important in the immune response in the autoimmune disease rheumatoid arthritis. This assay provides
direct evidence of inhibition of PPI of two proteins on different cell surfaces.

METHOD SUMMARY
The proximity ligation assay (PLA) technique has been used to study protein–protein interactions (PPI) within a particular
cell or to study the PPI of cell surface proteins that are expressed on the same cell. Here, for the first time, we report a
PLA to be used on the surface of different cells. We have used this technique to visualize the interactions between proteins
present on Jurkat (a nonadherent cell line) and HFLS-RA (an adherent cell line) cells in the same experiment. The assay
was performed using the Duolink ® II assay kit (Sigma Aldrich or Olink Bioscience, Uppsala, Sweden).
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In almost all physiological processes,
the medium for communication between
two cells is facilitated by the interaction of
proteins [1]. The up- or down-regulation of
proteins and the deregulated interaction
of these proteins usually lead to disease
conditions. Rational drug designs targeting

these protein–protein interactions (PPI)
have gained much popularity in the past
decade [2,3]. Hence, methods to study
PPIs and their inhibition is important. Many
proteins interact at the cell surface to send
signals inside the cell from the extracellular
region, and PPI on the cell surface are
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Figure 1. Protein–protein interactions of CD2–CD58 and its detection using proximity ligation assay.
(A) Crystal structure of complex of CD2–CD58 (PDB ID: 1QA9) showing adhesion domain of proteins.
(B and C) A schematic diagram of PPI between CD2 and CD58 from T cells and HFLS-RA cells and
detection of PPI using PLA.
HFLS-RA: Human fibroblast-like synoviocyte-rheumatoid arthritis; PLA: Proximity ligation assay; PPI:
Protein–protein interaction.
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targeted for drug discovery [4,5]. Epidermal
growth factor receptor as well as CD2–
CD58 proteins have been used for targeting
cancer and immunomodulation [6,7].
Among the cell surface proteins that assist
communication between cells, CD2–CD58
PPI plays a key role in T-cell signaling and
has implications in autoimmune diseases
such as rheumatoid arthritis (RA). Cyclic
peptides that were modified for stability
using sunflower trypsin inhibitor template
(SFTI) previously used to target CD2–CD58
interaction [8] have been used as inhibitors
of PPI in this study. It was hypothesized
that these peptides will mimic the CD2
adhesion domain and will bind to CD58
protein, which ultimately will interrupt the
CD2–CD58 PPIs. SFTI-a peptide binds to
the CD58 protein and inhibits CD2–CD58
interaction. The inhibition of PPIs results in
the modulation of immune response. It was
reported that SFTI-a peptide was found
to be a potent compound for inhibiting
cell adhesion in the immune response
in cell-based in vitro and ex vivo assays
to suppress T-cell immune response [8].
It was therefore important to investigate
whether the designed peptides inhibit the
CD2–CD58 PPI by the mechanism we
anticipated in the hypothesis. Detailed
interaction between proteins CD2 and
CD58 was elucidated by the crystal
structure of CD2–CD58 complex (Figure
1A) [9]. There are ten salt bridges and five
hydrogen bonds between the CD2 and
CD58 adhesion domains and, although the
interaction is relatively weak (Kd ∼1–10 μM),
it is highly specific, making it an important
interaction in the immune response.
Conventionally, coimmunoprecipitation
with western blot technique is used to
detect protein–protein interactions [10].
The proximity ligation assay (PLA) is a new
powerful technique not only to visualize
protein–protein interactions but also
to quantify protein–protein interactions
and their inhibition by small molecules,
peptides and antibodies. Unlike traditional
immunocytochemistry, which displays only
co-localization of proteins, the PLA helps
to detect and visualize protein–protein
interactions using a fluorescence probe
in a native state of the cells in vitro and in
samples from in vivo studies [11–15].
In PLA, the PPI can be detected
using primary antibodies and secondary
antibodies/probes against the specific
proteins participating in the PPI. The
protein-specific primary antibodies act
www.BioTechniques.com
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as binding sites for species-specific
secondary antibodies/probes, which
are attached to DNA oligonucleotides.
When these PLA probes bind to the target
and are within the required proximity
(distance ≤ 40 nm), DNA ligation occurs,
linking both PLA probes upon incubating
with ligase. After addition of polymerase,
the DNA-ligated circles will be amplified in
numbers to which labeled complementary
oligonucleotide probes will be added, and
they will show bright red fluorescent spots.
In short, we can visualize the protein–
protein interactions using fluorescent
probes [13]. To date, researchers have
successfully used the PLA technique to
evaluate the PPI between two proteins
present on the same cells [14]. Here,
for the first time, we employed PLA to
visualize the interaction between CD2
and CD58 proteins that are present on
two different cells, Jurkat cells and human
fibroblast-like synoviocyte-rheumatoid
arthritis (HFLS-RA) cells, respectively.
In an effort to elucidate the entire
protein network (interactome) of the
human body, details of protein–protein
interaction elucidation are important
to obtain a global picture of biological
processes in the body [1]. Deregulation of
PPI is also important in human diseases.
Thus, elucidating PPI between two cells
using PLA helps to understand the
cellular communication between the two
cells. Furthermore, the inhibition of PPI
by drug-like molecules or modulation of
PPI can be quantified using this assay.
Since antibodies are used for labeling
particular proteins, the assay detects
highly specific interactions. The assay also
provides information on co-localization of
proteins when the two cells make contact.
Since immune cells make contact during
immune response, this assay is useful
for studying proteins involved in the
immune network and complements the
existing assays used to study protein–
protein interactions at the immunological
synapse [16,17]. A schematic diagram of
the proposed PLA for proteins on different
cells is shown in Figure 1B & C. CD2 is
known to be expressed on T cells. CD58
is expressed on all epithelial cells but
is known to be on antigen-presenting
cells [18,19]. We used HFLS-RA cells as
a model for antigen-presenting cells that
express CD58. In rheumatoid arthritis,
CD58 is known to be overexpressed,
and this leads to recruitment of T cells
Vol. 65 | No. 3 2018
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Figure 2. Expression of CD58 protein on HFLS-RA cells. (A–D) Verified by flow cytometry without
FITC CD58 antibody and upon addition of 50, 100 and 200 μM of FITC CD58 antibody, respectively.
(E–F) Confocal microscopy images of HFLS-RA cells labeled with FITC-CD58. Nuclei stained with DAPI
(blue).
FITC: Flurescein isothiocyanate; HFLS-RA: Human fibroblast-like synoviocyte-rheumatoid arthritis.

at the joints, causing inflammation [20].
Thus, HFLS-RA cells that express CD58
serve as a good model for studying CD58
protein and its importance in the immune
response.

151

Materials & methods
Cell lines/cells
T-leukemia Jurkat cell line was purchased
from the American Type Culture Collection
www.BioTechniques.com
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(MD, USA). The cells were maintained
in RPMI1640 medium (with 10% FBS
and 0.1 mg/ml penicillin/streptomycin).
HFLS-RA cells were purchased from
Cell Applications, Inc. (CA, USA) and
were maintained in human synoviocyte
medium provided by Cell Applications,
Inc.

Primary a
 ntibodies & PLA kit
Specific primary antibodies against
CD58 (sc-6983, RRID: AB_2076111)
c-terminus goat polyclonal and CD2
(sc-365017, RRID: AB_10707813) mouse
monoclonal were purchased from Santa
Cruz Biotechnology (TX, USA). PLA in situ
red mouse/goat kit was purchased from

Duolink/Sigma Aldrich (MO, USA). This
kit includes mouse and goat secondary
antibodies with probes, blocking solution,
wash buffers A and B, amplification
solution ligase solution, and detection
reagent.

Peptide synthesis
Synthesis of cyclic peptide SFTI-a,
C yclo(CK ASAPPSCYDGDD), was
carried out in three major steps: 1) Linear
sequence synthesis with an automatic
peptide synthesizer (Protein Technologies,
Inc., AZ, USA); 2) head-to-tail cyclization;
and 3) disulfide bond formation. For
fluorescent labeling of peptide SFTI-a, Lys
in the peptide sequence was replaced with

A
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Figure 3. Protein–protein interaction and its inhibition indicated by proximity ligation assay using
T cells and HFLS-RA cells. Expanded regions of (A) PPI without treatment showing red fluorescence
dots. Nuclei are shown stained blue with DAPI. (B) Bright field image showing HFLS-RA cells and T
cells with PLA red fluorescence dots. (C & D) PLA in the presence of compound SFTI-a at a concentration of 100 μM. Notice the decrease in the number of red dots, indicating PPI inhibition between CD2
and CD58.
HFLS-RA: Human fibroblast-like synoviocyte-rheumatoid arthritis; PLA: Proximity ligation assay; PPI:
Protein–protein interaction.
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Lys containing an azide side chain. The
azide side chain was used to conjugate
fluorescent label 4,4-difluoro-4-bora3a,4a-diaza-s-indacene (BODIPY) [21],
resulting in the conjugate Cyclo(CK(BODIPY )-ASAPPSCYDGDD). The
detailed procedure for synthesis of the
peptide is described in our previous
work [8]. Peptides SFTI-a and SFTI-a with
lysine azide (N3) and fluorescence-labeled
SFTI-a were purified by preparative HPLC
(Waters Corp., MA, USA) using acetonitrile
and water containing 0.1% TFA. Molecular
weights of the synthesized peptide and
the conjugate were confirmed by mass
spectrometry. BODIPY was obtained from
Dr Vicente, Department of Chemistry,
Louisiana State University, LA, USA.

Flow cytometry
Flow cytometry was used to determine
the CD58 expression on HFLS-RA cells
with a flurescein isothiocyanate (FITC)labeled CD58 mouse monoclonal antibody
(Catalog number: sc-81734, Santa Cruz
Biotechnology, TX, USA). In 1.5-ml
Eppendorf tubes, 100 μl of HFLS-RA
cell suspension containing approximately
1 × 10 6 cells suspended in PBS was
added. Then, 100 μl of different FITC
CD58 antibody concentrations (200, 100
and 50 μM) prepared in PBS from stock
solution were added and incubated at 4°C
for 1 h. After incubation, the mixture was
centrifuged at 1000 rpm for 10 min, and
pellets were transferred to flow cytometry
tubes after resuspending with 2 ml of
cold PBS. A FACSCalibur flow cytometry
instrument (BD Biosciences, CA, USA)
operated with CellQuest Pro software
(BD Biosciences) was used, and the data
were further analyzed by using the FlowJo
program (v10; FlowJo, OR, USA). 10,000
cells were analyzed, and all samples
were analyzed with FL1 fluorescence and
side-scatter detectors for dot plots. Dot
plots and histograms for cell populations
according to fluorescence (FL1) were
plotted for different concentrations of FITC
CD58 antibody. Cells alone without FITC
CD58 antibody were used as a negative
control for the experiment.

Expression of CD58 on
HFLS-RA cells using microscopy
HFLS-RA cells were grown to confluency,
and 10,000 cells were coated onto chamber
slides. After 48 h at 37°C with 5% CO2, the
medium was removed from each well and
www.BioTechniques.com
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chilled, and enough methanol was added
to cover the surface for fixing the cells. After
incubating the slides for 15 min at -20°C,
the methanol was removed, and PBS was
used to hydrate the slides. The slides were
then washed one more time with PBS.
FITC-labeled CD58 mouse monoclonal
antibody (Santa Cruz Biotechnology) was
added to the cells and incubated for 1 h.
After washing with PBS, cover slips were
mounted, and the cells were visualized
under a microscope. Images were taken
at 40x magnification using the EVOS FL
cell imaging system microscope with color
CCD camera (Life Technologies, NY, USA).

PLA

Step 1: Coating of cells in
eight-well chamber slides
• Both T cells and HFLS-RA cells were
grown to 70% confluency.
• Approximately 20,000 Jurkat cells were
added to each well, and the chamber slides
were incubated for 30 min at 37°C with 5%
CO2.
• Approximately 10,000 HFLS-RA cells
were treated with different concentrations
of SFTI-a peptide separately for 2 h at 4°C
and added over Jurkat cells that were previously coated onto the well chamber slides.
• The slides were incubated for 48 h at
37°C with 5% CO2.
Step 2: Blocking & fixing
• The medium was gently removed from
the corners of the wells.
• Enough chilled methanol to cover the
surface was added to each well for fixing
the cells.
• After incubating the slides for 15 min
at −20°C, the methanol was removed, and
PBS was used to hydrate the slides.
• The slides were washed once more
with PBS.
• Two drops of blocking solution was
added to each well, and they were incubated
for 90 min at room temperature in a moist
chamber.
Step 3: Primary antibody addition
• The blocking solution was removed,
and the slides were washed gently with
PBS.
• The CD58 and CD2 (Santa Cruz
Biotechnology, TX, USA) primary antibodies
were used at a dilution of 2:100 by diluting
with antibody diluent solution provided in
kit (2 μl [CD58 Ab] + 2 μl [CD2 Ab] + 196 μl
antibody diluent solution per well).
Vol. 65 | No. 3 2018
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• After addition of primary antibody
solution, the slides were incubated overnight
at 4°C in a moist chamber with gentle
shaking.
Step 4: Addition of probes
• The primary antibody solution was
removed, and each well was washed very
gently with 100 μl of PBS.
• The probe solution was prepared
using 1:1:4 ratio of positive probe:negative
probe:antibody diluent solution, respectively.
• After removing PBS, approximately
80 μl of probe solution was added to each
well, which were incubated at 37°C for 1 h
in a moist chamber.
Step 5: Addition of ligase solution
• The probe solution was discarded, and
all wells were washed twice with 100 μl of
wash buffer A.
• Ligase solution was prepared by mixing
together 16 μl of ligation solution + 2 μl of
ligase + 62 μl of high purified water.
• 80 μl of this freshly prepared ligase
solution was added gently to each well,
which were incubated
at 37°C for 30 min in a
moist chamber.
Step 6: Addition of
amplification and
polymerase solution
• All procedures
from this step forward
were carried out in a
dark (light-protected)
environment.
• After removing
the ligase solution,
the wells were washed
gently twice with wash
buffer A.
• A m p li f ic atio n /
polymerase solution
was prepared by
mixing together 1 μl
polymerase + 16 μl
amplification (red)
solution + 63 μl
purified water.
• 80 μl of the above
solution was added to
each well in the dark,
and the plates were
incubated in a 37°C
moist chamber in the
dark for 100 min.

153

Step 7: Final washing
• Amplification/polymerase solution was
removed from each well, and they were
washed gently twice with 120 μl of wash
buffer B.
• 0.01x wash buffer B (in phosphatebuffered saline [PBS]) was prepared, and
each well was washed with this solution.
• The well on slides were removed (wells
are removed after all the washing step to
prepare the slide for microscopic imaging).
• Keeping the slide surface slightly wet
with 0.01x wash buffer B, a small amount
of mounting medium with DAPI solution was
added to the slide.
• Coverslips were placed over the slides,
and images were obtained by using an
Olympus Fluoview 1.0 confocal microscope
with DAPI and Texas Red filters.
Wash buffers A and B were provided
in the kit. The composition of the buffers is
not disclosed by the vendor. A bio-protocol
by Lin et al. [22] provides the composition
of Duolink in situ buffers A and B. The
incubation time of 48 h was established by
carrying out PLA at 24- and 48-h times.
At 48 h, T cells and HFLS-RA cells were
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Figure 4. Protein–protein interaction and its inhibition indicated by proximity ligation assay using different concentrations of SFTI-a. (A) HFLS-RA and T
cells in the absence of peptide showing PPI as indicated by red dots. (B) 50 nM, (C) 250 nM, (D) 1 μM, (E) 10 μM, (F) 50 μM, (G) 100 μM of SFTI-a, (H)
BODIPY conjugate of SFTI-a. Note the green fluorescence on HFLS-RA cells due to binding of a conjugate of SFTI-a to CD58 on cells. Conjugate was also able
to inhibit PPI as shown by a decrease in red fluorescence compared to control without any peptide. (I) HFLS-RA cells only, (J) T cells only, (K) quantification
of PPI inhibition by PLA and decrease in fluorescence at different concentrations of peptide SFTI-a. Nuclei are shown stained blue with DAPI.
HFLS-RA: Human fibroblast-like synoviocyte-rheumatoid arthritis; PLA: Proximity ligation assay; PPI: Protein–protein interaction.

adherent, and washing steps did not wash
away all the cells.

Controls
Control experiments were conducted with
HFLS-RA cells and T cells without addition
of primary antibodies to CD2 and CD58 but
with addition of secondary antibodies and
PLA probes. Experiments were performed
as described in steps 1–7 above.
Experiments with HFLS-RA cells and T
cells were arried out as described above by
adding primary and secondary antibodies
only to CD58 and with PLA probes.
Vol. 65 | No. 3 2018
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PLA experiments were performed
with HFLS-RA cells and T cells separately
without co-culture.

Microscopy & analysis
The microscopic visualization was carried
out on an Olympus Fluoview FV10i
confocal microscope. DAPI (excitation
359, emission 461) and Texas Red
(excitation 595, emission 612) filters
were used for detection purposes at 60x
zoom. For SFTI-a BODIPY conjugate, a
Mg+ green (excitation 507, emission 531)
filter was used. Different images were

154

taken from each well containing different
concentrations of SFTI-a and cells only. All
images were taken in a single plane and at
60x magnification.
In the ImageJ software, the counting
was done separately for the DAPI and the
red fluorescence PLA dots for each image.
Before counting, the color threshold was
adjusted such that the objects were
stained entirely but were distinctively
highlighted. To separate overlapping
objects, the settings used were: Process
> Binary > Watershed. The objects were
then analyzed using setting: Analyze >
www.BioTechniques.com
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Colocalization of CD2 & CD58
using HFLS-RA & T cells
HFLS-RA cells and T cells were grown
to confluency and coated onto chamber
slides as described in Step 1. The cells were
then fixed as described in Step 2. After the
blocking solution was removed, the cells
were washed with PBS and fluorescently
labeled antibodies to CD2 (PE-CF594 Mouse
Anti-Human CD2, BD BioSciences Catalog
number: 562319) and CD58 (Santa Cruz
Biotechnology, Catalog number: sc-81734)
were added. Cells were incubated for 2 h at
room temperature in a moist chamber with
gentle shaking. The slides were washed and
mounted with mounting media with DAPI.
Cells without addition of any antibody were
used as controls. Images were taken with
Olympus BX63 fitted with deconvolution
optics using DAPI, FITC and Texas Red
filters at 40x magnification and processed
by using CellSens dimension software.

Results & discussion
Transient interactions between cells
carried out via cell surface proteins play
a key role in the immune system for generating an immune response. Protein–
protein interactions between CD2 and
CD58 help to stabilize and generate
signaling in T-cell autoimmune response.
CD2 is upregulated upon T-cell activation,
and CD58 is overexpressed in antigenpresenting cells in autoimmune diseases
such as RA. HFLS-RA cells derived from
human RA cells provide a good model
to bind to T cells. These cells are known
to line the joints, producing synovial
fluid. HFLS-RA cells are used to study
signaling pathways that are important in
the development of joint inflammation and
RA [23–25]. Fibroblast synoviocytes are
Vol. 65 | No. 3 2018

known to express adhesion or costimulatory molecules that help them to act
as antigen-presenting cells [26]. Cell
adhesion interactions between adherent
and nonadherent cells have been studied
using fluorescent probes [27] and PLA has
been utilized to study PPI in nonadherent
cells [28,29].
The expression of CD58 on HFLS-RA
cells was confirmed by flow cytometry
and microscopy using FITC-labeled
anti-CD58 that binds to the adhesion
domain of CD58 (Figures 2A–F). Figure
2A shows HFLS-RA cells without fluorescently labeled CD58 antibody with most
of the cells in the left lower quadrant and
a histogram with cells on the left side.
Upon addition of different concentrations
of FITC-CD58 antibody, the cell population
moved to the right side in the histogram,
indicating the number of cells with
FITC-CD58 labeling (Figures 2B–D). The
majority of the cell population shifted to
the right side of the histogram, indicating
expression of CD58 on HFLS-RA cells.
This was further confirmed by confocal
microscopy (Figure 2E & F) where cells
showed green fluorescence outside of the
nucleus, indicating cell surface expression
of the CD58 protein. Jurkat cells are
known to express the CD2 protein.
Further, we confirmed the colocalization
of CD2 and CD58 using fluorescently
labeled antibody to CD2 (Texas red) and
CD58 (FITC) in a co-culture of HFLS-RA
cells and T cells using microscopy. The
presence of red and green fluorescence
in the co-cultured cells on slides clearly
indicates the co-localization of CD2 and
CD58 (Supplementary data). To study
the interactions of CD2 and CD58 from
T cells and HFLS-RA cells, the PLA was
employed. One of the hurdles faced in the
development of the assay was a problem
with nonadherent Jurkat cells. The PLA
involves several steps of washing, and a
nonadherent cell will create a problem
because several washing steps in which
a number of nonadherent cells wash
away is significant. To overcome this
problem, we incubated the Jurkat cells
first on chamber well plates and added
HFLS-RA cells, which are adherent cells.
Incubating HFLS-RA cells with Jurkat
cells helped the Jurkat cells to immobilize
during washing. Thus, we were successfully able to evaluate the PPI by PLA with
the use of two different cell lines. When T
cells were incubated with HFLS-RA cells
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without any peptide, SFTI-a treatment
and PLA was performed, there were
number of red dots (Figures 3 & 4) of
fluorescence due to CD2–CD58 interactions. After treatment with 100 μM SFTI-a
peptide, there was a significant decrease
in red dots (Figures 3C & D), indicating PPI
inhibition. Cells that were incubated with
different concentrations of SFTI-a peptide
showed a significant decrease in bright red
spots. SFTI-a showed dose-dependent
inhibition of the interaction between CD2
and CD58 proteins present on Jurkat cells
and HFLS-RA cells, respectively (Figure
4B–G). As controls, the PLA assay was
carried out on individual cells (T cells and
HFLS-RA cells) as well as co-culturing the
HFLS-RA cells and T cells and adding
primary and secondary antibodies to only
HFLS-RA cells and T cells (Figure 4I &
J). Control experiments when visualized
under a microscope did not show any red
fluorescence dots, indicating the specificity of the assay. These results indicate
that PPI can be detected between the
two cells as shown by red fluorescence
using PLA assay. Inhibition of PPI between
the two cells can be visualized using
microscopy. Furthermore, inhibition of PPI
can be quantified. The number of fluorescence red dots was quantified using
ImageJ software, and the data (Figure
4K) show a clear inhibition of PPI by
SFTI-a peptide. The data generated from
the experiment were analyzed by SAS
software with GLM code. The statistical
analysis indicated that the PPI inhibition
observed with all concentrations of SFTI-a
peptide (10, 50 and 100 μM) was significant in comparison with that of untreated
wells with p < 0.0001 (Figure 4K). SFTI-a
conjugate is a fluorescently labeled
peptide with BODIPY attachment.
The experiment with SFTI-a conjugate
treatment showed that SFTI-a peptide
was bound to the cell surface of HFLS-RA
cells as shown by green fluorescence of
BODIPY (Figure 4H). Thus, the peptide
and conjugate bind to CD58 on the cell
surface and inhibit the interaction between
Jurkat cells and HFLS-RA cells. This was
determined by significant inhibition of the
interactions of CD2 and CD58 proteins
(decrease in bright red spots) present on
different cells (Figure 4K). The experiment
indicated that in even lower concentrations of SFTI-a (50 and 250 nM), there was

Vol. 65 | No. 3 2018
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a significant reduction in a number of red
dots compared with control (p < 0.001).
Overall, we employed the PLA to study
PPI between two cell surface proteins on
different cells. We have carried out this
assay on floating and adherent cells. It
is particularly useful to study immune
cells, as the interaction between immune
cells involves several different proteins.
The assay can also be used to study
PPI between adherent cells as well as
PPI between cells if the cells’ transiently
express proteins on the cell surface.

Pitfalls & practical solutions
Jurkat cells are floating cells, and there can
be seven or more washing steps in PLA.
Hence, the number of Jurkat cells needed
is relatively large.
Washing steps must be done carefully,
as adhesion interaction between immune
cells is relatively weak, and it is possible to
wash away most of the cells used for the
study.

Open access
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